CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
比较idecabtagene vicleucel（ide-cel，bb2121）与常规治疗（CC）用于既往暴露于三类药物的复发/难治性多发性骨髓瘤（RRMM）患者的疗效。
采用匹配调整间接比较，使用关键性II期单臂KarMMa试验（NCT03361748）的患者个体数据，以及针对接受大量既往治疗RRMM患者、规模最大的独立观察研究MAMMOTH的汇总数据。
与CC相比，ide-cel改善总缓解率（优势比5.30；95% CI 2.96–9.51）、无进展生存期（风险比0.50；95% CI 0.36–0.70）和总生存期（风险比0.37；95% CI 0.25–0.56）。
结果提示，在这一接受大量既往治疗的RRMM患者群体中，与CC相比，ide-cel可改善临床结局。
Aim: To compare the efficacy of idecabtagene vicleucel (ide-cel, bb2121) versus conventional care (CC) in triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Patients & methods: A matching-adjusted indirect comparison was conducted using individual patient-level data from the pivotal, phase II, single-arm KarMMa trial (NCT03361748) and aggregate-level data from MAMMOTH, the largest independent observational study of CC in heavily pretreated RRMM patients.
Results: Ide-cel improved overall response rate (odds ratio: 5. 30; 95% CI: 2. 96-9. 51), progression-free survival (hazard ratio: 0. 50; 95% CI: 0. 36-0. 70) and overall survival (hazard ratio: 0. 37; 95% CI: 0. 25-0. 56) versus CC. Conclusion: These results suggest ide-cel offers improvements in clinical outcomes relative to CC in this heavily pretreated RRMM population.
MEMBER ACCOUNT
登录成功会直接打开下一页。
